3D printing of personalized medicine.

We develop medicines printed at the exact dose, for the specific patient, on demand, and open our platform to partners in pharma, pharmacy, telehealth and government.

Partner with us Investor presentation

CSE: PHRM · OTCQB: PHRRF

CraftTab 4-in-1 polypill, a multi-layer 3D-printed tablet, held between two fingers

Assorted 3D-printed dosage forms: tablets, chewables and gummies

Liquid-filled 3D-printed chewable held in a gloved hand

I'm here to…

InvestCatalysts, filings and alertsInvestors →Partner or licenseSix ways to work with usPartnering →Use the platformPrinters, formulation and contract manufacturingM3DICINES ↗Research or preparednessCollaborations and the emergency node networkPreparedness →Read newsNewsroom, media kit and contactNewsroom →

Exclusive North American CraftMake™ distributor

U.S. 503A Center of Excellence

Partnered GMP contract manufacturer

The opportunity

The long tail of dose: medicines mass manufacturing was never built to make.

Conventional manufacturing only pays at hundreds of thousands of identical units. Five groups of patients fall outside that.

Personalized peptidesTelehealth patients who need a dose made for them

Rare and ultra-rare diseasesFew patients, weight-based doses, often no approved treatment

Clinical and special-access supplyMany strengths, a few hundred units each

Emergency countermeasuresStockpile and special-population supply

Discontinued medicinesVolume never justified a production line

Why pharmaceutical 3D printing →

Business model

Two pillars. One platform.

The pipeline creates proprietary value. Partnering creates reach, adoption and recurring revenue, and surfaces new products.

We ownthe products and placement infrastructure

Personalized 503A products, including peptides and ketamine

FDA rare and ultra-rare disease programs

Psychedelic medicines and discontinued medicines

A national emergency preparedness network

Explore the pipeline →

We openthe platform to partners

Exclusive CraftMake™ distribution in North America

Formulation licensing and white-label products

CDMO services and research collaborations

Emergency-readiness contracts with governments

Ways to partner →

Our platform

One validated recipe prints any dose.

1 · Formulate

Validated formulation

Proprietary blends, GRAS excipients and printed geometries.

2 · Personalize

Digital recipe

Print files, parameters and methods: the manufacturing instructions for each dose.

CraftMake Production Plus pharmaceutical 3D printer

3 · Print

CraftMake™ prints it

GMP-ready, heat-free and UV-free, with a digital batch record for every dose.

1%Precision

No heat, no UVRoom-temperature printing

8*Dosage forms

4Release profiles

Our platform See CraftMake™ on M3DICINES ↗

*Oral films to be confirmed with Craft Health. 1% reflects Craft Health system specifications.

Product pipeline

Small batches, big gaps.

Our pipeline spans five areas where a precise dose, a combination or a small batch makes a medicine possible.

Explore the pipeline →

ProgramStatusNext milestone

503A personalized products

StatusLaunch planned

Next milestoneFirst launches Q4 2026; ketamine dissolvable tablet Q1 2027

Rare pediatric disease program

StatusDesignations

Next milestoneApplications October 2026 · NDA Q4 2028 (target)

Ultra-rare disease program

StatusEvaluating

Next milestoneProgram selection, 2027–2028

Psychedelic medicines

StatusPlanned

Next milestoneTrial and access supply, 2027–2028

Discontinued medicines

StatusEvaluating

Next milestoneCandidate selection, 2027–2028

Timelines are internal estimates and forward-looking. 503A products are compounded for individual patients and are not FDA-approved.

503A personalized productsPeptides, Rx wellness and ketamine for telehealthLearn more →Rare & ultra-rare diseasesWeight-banded doses with priority review voucher potentialLearn more →Psychedelic medicinesPrecisely dosed supply for trials and special accessLearn more →Discontinued medicinesBringing back medicines patients still needLearn more →Medical countermeasuresA network of qualified printing nodes for emergenciesLearn more →

Partnering

Six ways to work with PharmaTher.

1 · Place

CraftMake™ distribution

Bring GMP-ready 3D printing in-house, with validated formulations from day one.

2 · License

Formulation licensing

M3DICINES™ formulations for personalized doses, combinations and controlled release.

3 · Sell

White-label products

Pharma, peptide and nutraceutical products for telehealth and consumer-health brands.

4 · Develop

CDMO services

Formulation, clinical trial supply and small-batch manufacturing.

5 · Discover

Research collaborations

Feasibility and formulation science with pharma, universities and government.

6 · Prepare

Emergency readiness

Qualified printer nodes that make countermeasures on demand.

Start a partnering conversation Bring 3D printing in-house on M3DICINES ↗

For investors

The opportunity in front of us.

US$295BPeptide therapeutics by 2033up from US$141B in 2025

US$1.2TPersonalized medicine by 2033up from US$567B in 2024

US$59BMedical countermeasures by 2030up from US$41B in 2025

Catalysts and what each unlocks

Q4 2026First 503A launches; CraftMake™ ordersProduct revenue begins

Q1 2027Ketamine dissolvable tablet; pre-IND meetingTelehealth sales; first ANDA payments expected

Next 12 monthsUp to 50 CraftMake™ placementsRecurring revenue and first nodes

2027–28Licences, readiness contracts, new programsUltra-rare, psychedelic, discontinued

Q4 2028Rare pediatric NDA (target)Path to orphan exclusivity

BeyondFirst FDA-approved printed medicinePotential priority review voucher

Market sizes are third-party estimates of total markets, not PharmaTher revenue. Targets and timelines are internal estimates and forward-looking. Forward-looking statements